Parvizi Maedeh, Fadai Farbod, Khodaei-Ardakani Moahammad Reza, Amin Gholamreza, Abdi Leila, Noroozi Mehdi, Ansari Iman
Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Galen Med J. 2019 Dec 29;8:e1334. doi: 10.31661/gmj.v8i0.1334. eCollection 2019.
(CE) is an established medicinal herb utilized for treating psychosis in Persian medicine. The aim of this study was to investigate the effect of CE combined with risperidone on the clinical symptoms and the cognitive impairment in patients diagnosed with schizophrenia.
In this triple-blind randomized placebo-controlled trial, the intervention group received a dose of 500 mg of CE in the form of a capsule to be taken twice a day accompanied by an appropriate dose of risperidone. The control group was presented with a placebo identical to that of the CE capsule plus the allocated dose of risperidone. The PANSS and SCoRS questionnaires were used to assess the status of subjects prior to the initiation of the intervention as well as being put to use at the end of the second, fourth, and eighth week post-intervention. Registering and recording intel concerning positive and negative symptoms felt by participants (PANNS), and a test to assess the cognitive impairment of the individuals.
After eight weeks of treatment, all negative and positive symptoms besides hostility and somatic concern exhibited a significant improvement in the CE group (P <0.05). In contrast, the CE placebo group displayed no substantial improvement in the cases of the positive, negative and general symptoms (P>0.05) regarding cognitive impairment, after eight weeks of treatment, all symptoms were greatly improved in the CE group (P<0.05), while the effect of the placebo on the patients cognitive impairment remained mostly stationary (P>0.05). Consequently, after eight weeks after the intervention, we can determine that the CE treatment has been noticeably more effective at improving positive, negative and cognitive symptoms of patients with schizophrenia.
The results of this study demonstrated that CE, possessing possible antioxidant and neuroprotective properties, safely improved the positive and negative symptoms, and cognitive impairment of patients with schizophrenia.
（CE）是一种在波斯医学中用于治疗精神病的既定草药。本研究的目的是调查CE联合利培酮对诊断为精神分裂症患者的临床症状和认知障碍的影响。
在这项三盲随机安慰剂对照试验中，干预组接受每日两次、剂量为500毫克的CE胶囊，并配以适当剂量的利培酮。对照组服用与CE胶囊相同的安慰剂加分配剂量的利培酮。采用阳性和阴性症状量表（PANSS）和精神分裂症认知功能评定量表（SCoRS）问卷在干预开始前以及干预后第二、第四和第八周结束时评估受试者的状况。记录和登记参与者所感受到的有关阳性和阴性症状的信息（PANNS），以及一项评估个体认知障碍的测试。
治疗八周后，除敌意和躯体关注外，CE组所有阴性和阳性症状均有显著改善（P<0.05）。相比之下，CE安慰剂组在阳性、阴性和一般症状方面没有显著改善（P>0.05）。关于认知障碍，治疗八周后，CE组所有症状均有显著改善（P<0.05），而安慰剂对患者认知障碍的影响大多保持不变（P>0.05）。因此，干预八周后，我们可以确定CE治疗在改善精神分裂症患者的阳性、阴性和认知症状方面明显更有效。
本研究结果表明，具有可能的抗氧化和神经保护特性的CE安全地改善了精神分裂症患者的阳性和阴性症状以及认知障碍。
